Loading company…
YGION Biomedical develops personalized neoantigen-based cancer vaccines.
Founded in 2022 and based in Vienna, Austria, YGION Biomedical develops individualized cancer vaccines using neoantigen peptides. Its CARGONAUT carrier delivers peptides to antigen-presenting cells, and its YGNITE platform creates personalized vaccines based on tumor genomics and bioinformatics. The company was founded by Wolfgang Fischl, Georg Casari, Alexander Seitz, Geert Mudde, and Gottfried Himmler. In May 2024, it raised EUR 15 million in Series A funding from the Austrian Angel Investors Association to develop its platform and advance YG-01.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in